Drug Patents Expiring in 2038
1. Adhansia Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10722473 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Nov, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 27, 2022 |
| M(M-82) | Jun 28, 2024 |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 February, 2019
Treatment: Method of treating attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
ADHANSIA XR family patents
2. Adlarity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10835499 | CORIUM | Systems and methods for long term transdermal administration |
May, 2038
(13 years from now) | |
| US10966936 | CORIUM | Systems comprising a composite backing and methods for long term transdermal administration |
Aug, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 11, 2025 |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient
Market Authorisation Date: 11 March, 2022
Treatment: A method of transdermal delivery of donepezil for treating mild, moderate and severe dementia of the alzheimer's type
Dosage: SYSTEM
More Information on Dosage
ADLARITY family patents
3. Airduo Digihaler patent
expiration
AIRDUO DIGIHALER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11351317 | TEVA PHARM | Drug delivery device with electronics |
Feb, 2038
(13 years from now) | |
|
US11351317 (Pediatric) | TEVA PHARM | Drug delivery device with electronics |
Aug, 2038
(13 years from now) | |
| US11357935 | TEVA PHARM | Drug delivery device with electronics |
Sep, 2038
(13 years from now) | |
| US11000653 | TEVA PHARM | Inhaler |
Dec, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER
More Information on Dosage
AIRDUO DIGIHALER family patents
4. Akeega patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11091459 | JANSSEN BIOTECH | Niraparib compositions |
Mar, 2038
(13 years from now) | |
| US11673877 | JANSSEN BIOTECH | Niraparib compositions |
Mar, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 11, 2026 |
Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient
Market Authorisation Date: 11 August, 2023
Treatment: NA
Dosage: TABLET
More Information on Dosage
AKEEGA family patents
5. Altreno patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11324710 | DOW PHARM | Topical pharmaceutical compositions for treating skin conditions |
Aug, 2038
(13 years from now) | |
| US10653656 | DOW PHARM | Topical pharmaceutical compositions for treating skin conditions |
Aug, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 23, 2021 |
Drugs and Companies using TRETINOIN ingredient
Market Authorisation Date: 23 August, 2018
Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older
Dosage: LOTION
More Information on Dosage
ALTRENO family patents
6. Alvaiz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11072586 | TEVA PHARMS INC | Solid state forms of eltrombopag choline |
Nov, 2038
(13 years from now) | |
Drugs and Companies using ELTROMBOPAG CHOLINE ingredient
Market Authorisation Date: 29 November, 2023
Treatment: Treatment of adult patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy
Dosage: TABLET
More Information on Dosage
ALVAIZ family patents
7. Arazlo patent expiration
ARAZLO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11311482 | BAUSCH | Topical compositions and methods for treating skin diseases |
May, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 18, 2022 |
Drugs and Companies using TAZAROTENE ingredient
Market Authorisation Date: 18 December, 2019
Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older
Dosage: LOTION
How can I launch a generic of ARAZLO before it's drug patent expiration?
More Information on Dosage
ARAZLO family patents
8. Armonair Digihaler patent expiration
ARMONAIR DIGIHALER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11351317 | TEVA PHARM | Drug delivery device with electronics |
Feb, 2038
(13 years from now) | |
|
US11351317 (Pediatric) | TEVA PHARM | Drug delivery device with electronics |
Aug, 2038
(13 years from now) | |
| US11357935 | TEVA PHARM | Drug delivery device with electronics |
Sep, 2038
(13 years from now) | |
| US11000653 | TEVA PHARM | Inhaler |
Dec, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER
More Information on Dosage
ARMONAIR DIGIHALER family patents
9. Aspruzyo Sprinkle patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11510878 | SPIL | Extended release multiparticulates of ranolazine |
Jan, 2038
(13 years from now) | |
| US10898444 | SPIL | Extended release multiparticulates of ranolazine |
Jan, 2038
(13 years from now) | |
Drugs and Companies using RANOLAZINE ingredient
Market Authorisation Date: 28 February, 2022
Treatment: NA
Dosage: GRANULES, EXTENDED RELEASE
More Information on Dosage
ASPRUZYO SPRINKLE family patents
10. Austedo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11813232 | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(13 years from now) | |
| US11179386 | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(13 years from now) | |
|
US11813232 (Pediatric) | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(13 years from now) | |
|
US11179386 (Pediatric) | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-751) | Aug 30, 2020 |
| New Chemical Entity Exclusivity(NCE) | Apr 03, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 03, 2024 |
| Orphan Drug Exclusivity(ODE-134) | Apr 03, 2024 |
| M(M-54) | Jun 24, 2024 |
| Pediatric Exclusivity(PED) | Dec 24, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
NCE-1 date: 25 December, 2023
Market Authorisation Date: 03 April, 2017
Treatment: A method of treating huntington's chorea
Dosage: TABLET
How can I launch a generic of AUSTEDO before it's drug patent expiration?
More Information on Dosage
AUSTEDO family patents
11. Austedo Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11813232 | TEVA | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(13 years from now) | |
| US11179386 | TEVA | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(13 years from now) | |
|
US11813232 (Pediatric) | TEVA | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(13 years from now) | |
|
US11179386 (Pediatric) | TEVA | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(13 years from now) | |
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of tardive dyskinesia
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
AUSTEDO XR family patents
12. Balversa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11077106 | JANSSEN BIOTECH | Cancer treatment |
Feb, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 12, 2024 |
| New Indication(I-930) | Jan 19, 2027 |
Drugs and Companies using ERDAFITINIB ingredient
NCE-1 date: 13 April, 2023
Market Authorisation Date: 12 April, 2019
Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 genetic alterations whose disease has progressed on or after at least one line of prior systemic the...
Dosage: TABLET
How can I launch a generic of BALVERSA before it's drug patent expiration?
More Information on Dosage
BALVERSA family patents
13. Baqsimi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10894133 | AMPHASTAR PHARMS INC | Device for dispensing a fluid product |
Jan, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 24, 2022 |
Drugs and Companies using GLUCAGON ingredient
Market Authorisation Date: 24 July, 2019
Treatment: NA
Dosage: POWDER
More Information on Dosage
BAQSIMI family patents
14. Barhemsys patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11357753 | ACACIA | Rescue treatment of post operative nausea and vomiting |
Feb, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2025 |
Drugs and Companies using AMISULPRIDE ingredient
NCE-1 date: 27 February, 2024
Market Authorisation Date: 26 February, 2020
Treatment: Treatment of post-operative nausea and vomiting
Dosage: SOLUTION
More Information on Dosage
BARHEMSYS family patents
15. Breztri Aerosphere patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11833292 | ASTRAZENECA AB | Drug delivery systems and related methods |
Oct, 2038
(13 years from now) | |
| US11331442 | ASTRAZENECA AB | Drug delivery systems and related methods |
Oct, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 23, 2023 |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient
Market Authorisation Date: 23 July, 2020
Treatment: NA
Dosage: AEROSOL, METERED
More Information on Dosage
BREZTRI AEROSPHERE family patents
16. Bynfezia Pen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10342850 | SUN PHARM | Octreotide injection |
May, 2038
(13 years from now) | |
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Market Authorisation Date: 27 September, 2024
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
BYNFEZIA PEN family patents
17. Cerdelga patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10888544 | GENZYME CORP | Methods for treating Gaucher disease |
Dec, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2019 |
| Orphan Drug Exclusivity(ODE) | Aug 19, 2021 |
| Orphan Drug Exclusivity(ODE-73) | Aug 19, 2021 |
Drugs and Companies using ELIGLUSTAT TARTRATE ingredient
NCE-1 date: 19 August, 2018
Market Authorisation Date: 19 August, 2014
Treatment: Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive metabolizers with mild hepatic impairment and are concurrently taking a strong or moderate cyp3a inhibitor
Dosage: CAPSULE
How can I launch a generic of CERDELGA before it's drug patent expiration?
More Information on Dosage
CERDELGA family patents
18. Consensi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10350171 | PURPLE BIOTECH | Celecoxib and amlodipine formulation and method of making the same |
Jun, 2038
(13 years from now) | |
| US10925835 | PURPLE BIOTECH | Celecoxib and amlodipine formulation and method of making the same |
Jun, 2038
(13 years from now) | |
| US10945960 | PURPLE BIOTECH | Celecoxib and amlodipine formulation and method of making the same |
Jun, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | May 31, 2021 |
Drugs and Companies using AMLODIPINE BESYLATE; CELECOXIB ingredient
Market Authorisation Date: 31 May, 2018
Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate
Dosage: TABLET
How can I launch a generic of CONSENSI before it's drug patent expiration?
More Information on Dosage
CONSENSI family patents
19. Cotempla Xr-odt patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11166947 | NEOS THERAPS INC | Effective dosing of a child for the treatment of ADHD with methylphenidate |
Jan, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 19, 2020 |
Drugs and Companies using METHYLPHENIDATE ingredient
Market Authorisation Date: 19 June, 2017
Treatment: Treatment of attention deficit hyperactivity disorder (adhd) in pediatric patients
Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
How can I launch a generic of COTEMPLA XR-ODT before it's drug patent expiration?
More Information on Dosage
COTEMPLA XR-ODT family patents
20. Cysview Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11235168 | PHOTOCURE ASA | Method of photodynamic therapy (PDT) for bladder cancer |
Jan, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 28, 2013 |
| M(M-220) | Feb 15, 2021 |
Drugs and Companies using HEXAMINOLEVULINATE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 May, 2010
Treatment: Detection of carcinoma in the bladder by photodynamic cystoscopy
Dosage: FOR SOLUTION
More Information on Dosage
CYSVIEW KIT family patents
21. Daptomycin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11759497 | XELLIA PHARMS APS | Daptomycin formulations |
Aug, 2038
(13 years from now) | |
| US12053502 | XELLIA PHARMS APS | Daptomycin formulations |
Aug, 2038
(13 years from now) | |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 30 January, 2023
Treatment: Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus blood stream infections
Dosage: POWDER
More Information on Dosage
DAPTOMYCIN family patents
22. Dsuvia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11672738 | VERTICAL PHARMS | Apparatus and methods for dispensing oral transmucosal dosage forms |
Feb, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 02, 2021 |
Drugs and Companies using SUFENTANIL CITRATE ingredient
Market Authorisation Date: 02 November, 2018
Treatment: NA
Dosage: TABLET
More Information on Dosage
DSUVIA family patents
23. Dyanavel Xr 10 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11590081 | TRIS PHARMA INC | Extended release amphetamine tablets |
Sep, 2038
(13 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
DYANAVEL XR 10 family patents
24. Dyanavel Xr 15 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11590081 | TRIS PHARMA INC | Extended release amphetamine tablets |
Sep, 2038
(13 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
DYANAVEL XR 15 family patents
25. Dyanavel Xr 20 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11590081 | TRIS PHARMA INC | Extended release amphetamine tablets |
Sep, 2038
(13 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
DYANAVEL XR 20 family patents
26. Dyanavel Xr 5 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11590081 | TRIS PHARMA INC | Extended release amphetamine tablets |
Sep, 2038
(13 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
DYANAVEL XR 5 family patents
27. Empaveli patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11040107 | APELLIS PHARMS | Dosing regimens and related compositions and methods |
Apr, 2038
(13 years from now) | |
| US11844841 | APELLIS PHARMS | Dosing regimens and related compositions and methods |
Dec, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-288) | Feb 08, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 14, 2026 |
| Orphan Drug Exclusivity(ODE-351) | May 14, 2028 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 14 May, 2025
Market Authorisation Date: 14 May, 2021
Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan twice weekly
Dosage: SOLUTION
More Information on Dosage
EMPAVELI family patents
28. Erleada patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10702508 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
Apr, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-808) | Sep 17, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 14, 2023 |
Drugs and Companies using APALUTAMIDE ingredient
NCE-1 date: 14 February, 2022
Market Authorisation Date: 14 February, 2018
Treatment: Treatment in combination with androgen deprivation therapy of non-metastatic, castration-resistant prostate cancer (nmcrpc) that improves metastasis free survival
Dosage: TABLET
How can I launch a generic of ERLEADA before it's drug patent expiration?
More Information on Dosage
ERLEADA family patents
29. Erzofri patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12128049 | LUYE INNOMIND PHARMA | Dosage regimen of paliperidone palmitate extended-release injectable suspension |
Oct, 2038
(13 years from now) | |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
Market Authorisation Date: 26 July, 2024
Treatment: Dosing regimen for the treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants by administering an initial dose of paliperidone palmitat...
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
ERZOFRI family patents
30. Evrysdi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11534444 | GENENTECH INC | Treatment of SMA |
Oct, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 27, 2025 |
| New Chemical Entity Exclusivity(NCE) | Aug 07, 2025 |
| M(M-270) | Oct 03, 2026 |
| Orphan Drug Exclusivity(ODE-334) | Aug 07, 2027 |
| Orphan Drug Exclusivity(ODE-400) | May 27, 2029 |
Drugs and Companies using RISDIPLAM ingredient
NCE-1 date: 07 August, 2024
Market Authorisation Date: 07 August, 2020
Treatment: Treatment of spinal muscular atrophy
Dosage: FOR SOLUTION
More Information on Dosage
EVRYSDI family patents
31. Fabhalta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11723901 | NOVARTIS | Uses of piperidinyl-indole derivatives |
Aug, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-949) | Aug 07, 2027 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2028 |
| Orphan Drug Exclusivity(ODE-456) | Dec 05, 2030 |
Drugs and Companies using IPTACOPAN HYDROCHLORIDE ingredient
NCE-1 date: 06 December, 2027
Market Authorisation Date: 05 December, 2023
Treatment: Treatment of primary immunoglobulin a nephropathy (igan)
Dosage: CAPSULE
More Information on Dosage
FABHALTA family patents
32. Ferriprox patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10940115 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(13 years from now) | |
| US11458103 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(13 years from now) | |
| US11357731 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(13 years from now) | |
| US11723874 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(13 years from now) | |
| US10780055 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(13 years from now) | |
| US10940116 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 14, 2016 |
| Orphan Drug Exclusivity(ODE) | Oct 14, 2018 |
| Orphan Drug Exclusivity(ODE-16) | Oct 14, 2018 |
| New Indication(I-859) | Apr 30, 2024 |
| Orphan Drug Exclusivity(ODE-417) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-418) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-419) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-420) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-421) | Apr 30, 2028 |
Drugs and Companies using DEFERIPRONE ingredient
Market Authorisation Date: 19 May, 2020
Treatment: Method of treating transfusional iron overload
Dosage: TABLET
How can I launch a generic of FERRIPROX before it's drug patent expiration?
More Information on Dosage
FERRIPROX family patents
33. Fintepla patent expiration
FINTEPLA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10603290 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
|
US11040018 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
|
US11759440 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
|
US11406606 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
|
US11786487 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
| US10452815 | UCB INC | Control system for control of distribution of medication |
Jun, 2038
(13 years from now) | |
|
US10452815 (Pediatric) | UCB INC | Control system for control of distribution of medication |
Dec, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 25, 2023 |
| New Indication(I-887) | Mar 25, 2025 |
| Orphan Drug Exclusivity(ODE-312) | Jun 25, 2027 |
| Orphan Drug Exclusivity(ODE-393) | Mar 25, 2029 |
| Pediatric Exclusivity(PED) | Sep 25, 2029 |
Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 25 June, 2020
Treatment: Use of cardiac monitoring and restricted distribution of fenfluramine to mitigate risk of cardiovascular toxicity in the treatment of seizures associated with dravet syndrome
Dosage: SOLUTION
How can I launch a generic of FINTEPLA before it's drug patent expiration?
More Information on Dosage
FINTEPLA family patents
34. Galafold patent expiration
Can you believe GALAFOLD received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11426396 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US12042489 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US12109205 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11304940 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11612594 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US12042488 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11357764 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11376244 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11612593 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11357765 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11633387 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11786516 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11903938 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Aug, 2038
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10471053 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US12042490 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11458128 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11666564 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US10857141 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US10849890 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US10849889 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US10857142 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US10874657 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US10874655 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US10874656 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11389437 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11389436 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US10792278 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US10792279 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US10799491 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US10806727 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11813255 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11278538 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11278537 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11278536 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11278539 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11278540 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US10251873 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11357761 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11357762 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| US11357763 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
| Orphan Drug Exclusivity(ODE-205) | Aug 10, 2025 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: The treatment of fabry patients
Dosage: CAPSULE
How can I launch a generic of GALAFOLD before it's drug patent expiration?
More Information on Dosage
GALAFOLD family patents
35. Gocovri patent expiration
Can you believe GOCOVRI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11077073 | SUPERNUS PHARMS | Methods of using amantadine compositions |
Aug, 2038
(13 years from now) | |
| US11065213 | SUPERNUS PHARMS | Amantadine compositions and preparations thereof |
Aug, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-769) | Aug 24, 2020 |
| New Product(NP) | Aug 24, 2020 |
| Orphan Drug Exclusivity(ODE) | Aug 24, 2024 |
| Orphan Drug Exclusivity(ODE-153) | Aug 24, 2024 |
Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 August, 2017
Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of GOCOVRI before it's drug patent expiration?
More Information on Dosage
GOCOVRI family patents
36. Iheezo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10792271 | HARROW EYE | Topical formulations of chloroprocaine and methods of using same |
Sep, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 27, 2025 |
Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 September, 2022
Treatment: Method of inducing ocular anesthesia
Dosage: GEL
More Information on Dosage
IHEEZO family patents
37. Ingrezza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11311532 | NEUROCRINE | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
Sep, 2038
(13 years from now) | |
| US11026939 | NEUROCRINE | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
Sep, 2038
(13 years from now) | |
| US11654142 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Nov, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 11, 2022 |
| New Indication(I-925) | Aug 18, 2026 |
| Orphan Drug Exclusivity(ODE-440) | Aug 18, 2030 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
NCE-1 date: 11 April, 2021
Market Authorisation Date: 11 April, 2017
Treatment: A method of treating huntington's chorea; Treatment of tardive dyskinesia
Dosage: CAPSULE
How can I launch a generic of INGREZZA before it's drug patent expiration?
More Information on Dosage
INGREZZA family patents
38. Ingrezza Sprinkle patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11026939 | NEUROCRINE | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
Sep, 2038
(13 years from now) | |
| US11311532 | NEUROCRINE | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
Sep, 2038
(13 years from now) | |
| US11654142 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Nov, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-925) | Aug 18, 2026 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
Market Authorisation Date: 30 April, 2024
Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea
Dosage: CAPSULE
More Information on Dosage
INGREZZA SPRINKLE family patents
39. Jesduvroq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11117871 | GLAXOSMITHKLINE | Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof |
Mar, 2038
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11649217 | GLAXOSMITHKLINE | Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof |
Mar, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 01, 2028 |
Drugs and Companies using DAPRODUSTAT ingredient
NCE-1 date: 01 February, 2027
Market Authorisation Date: 01 February, 2023
Treatment: A method of treating anemia
Dosage: TABLET
More Information on Dosage
JESDUVROQ family patents
40. Juluca patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12011506 | VIIV HLTHCARE | Combination and uses and treatments thereof |
Sep, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| New Combination(NC) | Nov 21, 2020 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 21 November, 2017
Treatment: NA
Dosage: TABLET
How can I launch a generic of JULUCA before it's drug patent expiration?
More Information on Dosage
JULUCA family patents
41. Klisyri patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10669236 | ALMIRALL | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide |
Sep, 2038
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11497750 | ALMIRALL | Methods of treating and/or preventing actinic keratosis |
Mar, 2038
(13 years from now) | |
| US10617693 | ALMIRALL | Methods of treating and/or preventing actinic keratosis |
Mar, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2025 |
| New Dosing Schedule(D-192) | Jun 07, 2027 |
Drugs and Companies using TIRBANIBULIN ingredient
NCE-1 date: 14 December, 2024
Market Authorisation Date: 14 December, 2020
Treatment: Topical treatment of actinic keratosis of the face or scalp
Dosage: OINTMENT
More Information on Dosage
KLISYRI family patents
42. Korlym patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10314850 | CORCEPT THERAP | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
Aug, 2038
(13 years from now) | |
| US10780097 | CORCEPT THERAP | Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
Aug, 2038
(13 years from now) | |
| US10231983 | CORCEPT THERAP | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
Aug, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 17, 2015 |
| Orphan Drug Exclusivity(ODE) | Feb 17, 2019 |
| Orphan Drug Exclusivity(ODE-22) | Feb 17, 2019 |
Drugs and Companies using MIFEPRISTONE ingredient
Market Authorisation Date: 17 February, 2012
Treatment: Treating cushing's syndrome
Dosage: TABLET
How can I launch a generic of KORLYM before it's drug patent expiration?
More Information on Dosage
KORLYM family patents
43. Lazcluze patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11453656 | JANSSEN BIOTECH | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same |
Apr, 2038
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11981659 | JANSSEN BIOTECH | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same |
Apr, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2029 |
Drugs and Companies using LAZERTINIB MESYLATE ingredient
NCE-1 date: 19 August, 2028
Market Authorisation Date: 19 August, 2024
Treatment: First-line treatment of adults with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 l858r substitution mutations, in combination with amivantam...
Dosage: TABLET
More Information on Dosage
LAZCLUZE family patents
44. Levolet patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10406108 | GENUS LIFESCIENCES | Thyroid hormone oral dosage forms and methods of using the same |
Mar, 2038
(13 years from now) | |
| US10231931 | GENUS LIFESCIENCES | Thyroid hormone oral dosage forms and methods of using the same |
Mar, 2038
(13 years from now) | |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 06 June, 2003
Treatment: NA
Dosage: TABLET
More Information on Dosage
LEVOLET family patents
45. Levulan patent expiration
LEVULAN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11571478 | SUN PHARM INDS INC | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
| US11077192 | SUN PHARM INDS INC | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
| US11690914 | SUN PHARM INDS INC | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
| US10357567 | SUN PHARM INDS INC | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
| US11135293 | SUN PHARM INDS INC | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-82) | Mar 12, 2013 |
| New Indication(I-766) | Mar 09, 2021 |
Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient
Market Authorisation Date: 03 December, 1999
Treatment: Treatment of actinic keratoses of upper extremities by photodynamic therapy
Dosage: SOLUTION
More Information on Dosage
LEVULAN family patents
46. Libervant patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11273131 | AQUESTIVE | Pharmaceutical compositions with enhanced permeation |
Jun, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 26, 2027 |
Drugs and Companies using DIAZEPAM ingredient
Market Authorisation Date: 26 April, 2024
Treatment: NA
Dosage: FILM
More Information on Dosage
LIBERVANT family patents
47. Liqrev patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11337979 | CMP DEV LLC | Liquid oral formulations for sildenafil |
Dec, 2038
(14 years from now) | |
| US11759468 | CMP DEV LLC | Liquid oral formulations for sildenafil |
Dec, 2038
(14 years from now) | |
| US11464778 | CMP DEV LLC | Liquid oral formulations for sildenafil |
Dec, 2038
(14 years from now) | |
| US12005062 | CMP DEV LLC | Liquid oral formulations for sildenafil |
Dec, 2038
(14 years from now) | |
Drugs and Companies using SILDENAFIL CITRATE ingredient
Market Authorisation Date: 28 April, 2023
Treatment: Liqrev is indicated for the treatment of pulmonary arterial hypertension (who group 1) in adults to improve exercise ability and delay clinical worsening
Dosage: SUSPENSION
More Information on Dosage
LIQREV family patents
48. Lorbrena patent expiration
Can you believe LORBRENA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11299500 | PFIZER | Crystalline form of lorlatinib free base hydrate |
Oct, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 02, 2023 |
| New Indication(I-847) | Mar 03, 2024 |
| Orphan Drug Exclusivity(ODE-217) | Nov 02, 2025 |
| Orphan Drug Exclusivity(ODE-218) | Nov 02, 2025 |
| Orphan Drug Exclusivity(ODE-219) | Nov 02, 2025 |
| Orphan Drug Exclusivity(ODE-349) | Mar 03, 2028 |
Drugs and Companies using LORLATINIB ingredient
NCE-1 date: 02 November, 2022
Market Authorisation Date: 02 November, 2018
Treatment: NA
Dosage: TABLET
More Information on Dosage
LORBRENA family patents
49. Lumakras patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10519146 | AMGEN INC | KRAS G12C inhibitors and methods of using the same |
May, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
| ODE*(ODE*) | May 28, 2028 |
| Orphan Drug Exclusivity(ODE-352) | May 28, 2028 |
Drugs and Companies using SOTORASIB ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: NA
Dosage: TABLET
More Information on Dosage
LUMAKRAS family patents
50. Lumason patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10232061 | BRACCO | Freeze-dried formulation for gas-filled microvesicles |
Jul, 2038
(13 years from now) | |
| US10335502 | BRACCO | Freeze-dried formulation for gas-filled microvesicles |
Jul, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-728) | Mar 31, 2019 |
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
| New Patient Population(NPP) | Nov 13, 2022 |
Drugs and Companies using SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES ingredient
NCE-1 date: 10 October, 2018
Market Authorisation Date: 15 October, 2014
Treatment: NA
Dosage: FOR SUSPENSION
More Information on Dosage
LUMASON family patents
51. Lutathera patent expiration
LUTATHERA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10596276 | AAA USA INC | Stable, concentrated radionuclide complex solutions |
Jul, 2038
(13 years from now) | |
| US11904027 | AAA USA INC | Stable, concentrated radionuclide complex solutions |
Jul, 2038
(13 years from now) | |
| US10596278 | AAA USA INC | Stable, concentrated radionuclide complex solutions |
Jul, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 26, 2023 |
| Orphan Drug Exclusivity(ODE-166) | Jan 26, 2025 |
| New Patient Population(NPP) | Apr 23, 2027 |
| Orphan Drug Exclusivity(ODE-479) | Apr 23, 2031 |
| Pediatric Exclusivity(PED) | Oct 23, 2031 |
Drugs and Companies using LUTETIUM LU 177 DOTATATE ingredient
NCE-1 date: 23 October, 2030
Market Authorisation Date: 26 January, 2018
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
LUTATHERA family patents
52. Mavenclad patent expiration
MAVENCLAD IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10849919 | EMD SERONO INC | Cladribine regimen for treating progressive forms of multiple sclerosis |
Nov, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 29, 2022 |
Drugs and Companies using CLADRIBINE ingredient
Market Authorisation Date: 29 March, 2019
Treatment: Treating non-early spms by administering oral cladribine at a fixed dose per patient, per body weight and per treatment year, which fixed dose is 1.75 +/- 0.2 mg/kg, to be administered within months 1...
Dosage: TABLET
How can I launch a generic of MAVENCLAD before it's drug patent expiration?
More Information on Dosage
MAVENCLAD family patents
53. Midazolam In 0.9% Sodium Chloride patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10966990 | INFORLIFE | Midazolam in flexible bags |
Jun, 2038
(13 years from now) | |
Drugs and Companies using MIDAZOLAM ingredient
Market Authorisation Date: 22 March, 2021
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of MIDAZOLAM IN 0.9% SODIUM CHLORIDE before it's drug patent expiration?
More Information on Dosage
MIDAZOLAM IN 0.9% SODIUM CHLORIDE family patents
54. Myfembree patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11793812 | SUMITOMO PHARMA | Methods of treating endometriosis |
May, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 26, 2024 |
| New Indication(I-898) | Aug 05, 2025 |
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
| M(M-289) | Jan 27, 2026 |
Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 26 May, 2021
Treatment: Management of moderate to severe pain associated with endometriosis
Dosage: TABLET
More Information on Dosage
MYFEMBREE family patents
55. Neffy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11173209 | ARS PHARMS OPERATION | Compositions for drug administration |
Feb, 2038
(13 years from now) | |
| US10576156 | ARS PHARMS OPERATION | Compositions for drug administration |
Feb, 2038
(13 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 09 August, 2024
Treatment: Nasal administration of epinephrine for the treatment of allergic reactions (type i), including anaphylaxis
Dosage: SPRAY
More Information on Dosage
NEFFY family patents
56. Norepinephrine Bitartrate In 0.9% Sodium Chloride patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10226436 | LONG GROVE PHARMS | Norepinephrine compositions and methods therefor |
Jan, 2038
(13 years from now) | |
| US10159657 | LONG GROVE PHARMS | Norepinephrine compositions and methods therefor |
Jan, 2038
(13 years from now) | |
| US11602508 | LONG GROVE PHARMS | Norepinephrine compositions and methods therefor |
Jan, 2038
(13 years from now) | |
| US10568850 | LONG GROVE PHARMS | Norepinephrine compositions and methods therefor |
Jan, 2038
(13 years from now) | |
| US11413259 | LONG GROVE PHARMS | Norepinephrine compositions and methods therefor |
Jan, 2038
(13 years from now) | |
| US10420735 | LONG GROVE PHARMS | Norepinephrine compositions and methods therefor |
Jan, 2038
(13 years from now) | |
Drugs and Companies using NOREPINEPHRINE BITARTRATE ingredient
Market Authorisation Date: 06 October, 2022
Treatment: Indicated to raise blood pressure in adult patients with severe, acute hypotension
Dosage: SOLUTION
More Information on Dosage
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE family patents
57. Nubeqa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11168058 | BAYER HEALTHCARE | Manufacture of a crystalline pharmaceutical product |
Feb, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 30, 2024 |
| New Indication(I-900) | Aug 05, 2025 |
Drugs and Companies using DAROLUTAMIDE ingredient
NCE-1 date: 31 July, 2023
Market Authorisation Date: 30 July, 2019
Treatment: NA
Dosage: TABLET
More Information on Dosage
NUBEQA family patents
58. Nuplazid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11452721 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(13 years from now) | |
| US10849891 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(13 years from now) | |
| US10449185 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(13 years from now) | |
| US10646480 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 29, 2021 |
Drugs and Companies using PIMAVANSERIN TARTRATE ingredient
NCE-1 date: 29 April, 2020
Market Authorisation Date: 28 June, 2018
Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis
Dosage: CAPSULE
How can I launch a generic of NUPLAZID before it's drug patent expiration?
More Information on Dosage
NUPLAZID family patents
59. Nymalize patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11517563 | AZURITY | Liquid nimodipine compositions |
Apr, 2038
(13 years from now) | |
| US11207306 | AZURITY | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(13 years from now) | |
| US11413277 | AZURITY | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(13 years from now) | |
| US10342787 | AZURITY | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(13 years from now) | |
| US10576070 | AZURITY | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(13 years from now) | |
| US11759457 | AZURITY | Liquid nimodipine compositions |
Apr, 2038
(13 years from now) | |
| US11806338 | AZURITY | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | May 10, 2020 |
| Orphan Drug Exclusivity(ODE-46) | May 10, 2020 |
Drugs and Companies using NIMODIPINE ingredient
Market Authorisation Date: 10 May, 2013
Treatment: A method for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (sah) from ruptured intracranial berry a...
Dosage: SOLUTION
How can I launch a generic of NYMALIZE before it's drug patent expiration?
More Information on Dosage
NYMALIZE family patents
60. Opvee patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458091 | INDIVIOR | Compositions and methods for the treatment of opioid overdose |
Jul, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 22, 2026 |
Drugs and Companies using NALMEFENE HYDROCHLORIDE ingredient
Market Authorisation Date: 22 May, 2023
Treatment: Treating opioid overdose
Dosage: SPRAY
More Information on Dosage
OPVEE family patents
61. Oriahnn (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12083227 | ABBVIE | Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis |
Aug, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 29, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
NCE-1 date: 23 July, 2022
Market Authorisation Date: 29 May, 2020
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)
Dosage: CAPSULE
How can I launch a generic of ORIAHNN (COPACKAGED) before it's drug patent expiration?
More Information on Dosage
ORIAHNN (COPACKAGED) family patents
62. Orilissa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11690854 | ABBVIE | Methods of treating heavy menstrual bleeding |
Apr, 2038
(13 years from now) | |
| US12102637 | ABBVIE | Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis |
Aug, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
Drugs and Companies using ELAGOLIX SODIUM ingredient
NCE-1 date: 23 July, 2022
Market Authorisation Date: 23 July, 2018
Treatment: Management of moderate to severe pain associated with endometriosis in a patient with moderate hepatic impairment
Dosage: TABLET
How can I launch a generic of ORILISSA before it's drug patent expiration?
More Information on Dosage
ORILISSA family patents
63. Orserdu patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10385008 | STEMLINE THERAP | Polymorphic forms of RAD1901-2HCL |
Jan, 2038
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10745343 | STEMLINE THERAP | Polymorphic forms of RAD1901-2HCl |
Jan, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2028 |
Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient
NCE-1 date: 27 January, 2027
Market Authorisation Date: 27 January, 2023
Treatment: Treatment of an er-positive breast cancer
Dosage: TABLET
More Information on Dosage
ORSERDU family patents
64. Osmolex Er patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10500172 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Feb, 2038
(13 years from now) | |
| US10213393 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Feb, 2038
(13 years from now) | |
| US10500171 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Feb, 2038
(13 years from now) | |
| US10213394 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Feb, 2038
(13 years from now) | |
| US10500170 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Feb, 2038
(13 years from now) | |
| US10512617 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Feb, 2038
(13 years from now) | |
| US11890261 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Feb, 2038
(13 years from now) | |
Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 February, 2018
Treatment: Treatment of drug-induced extrapyramidal reaction in adult patients; A process for treating a patient suffering from parkinson's syndrome and in need of treatment
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
OSMOLEX ER family patents
65. Otiprio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11246863 | ALK ABELLO | Ciprofloxacin otic composition and kits and method for using same |
Nov, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 10, 2018 |
| New Indication(I-770) | Mar 02, 2021 |
Drugs and Companies using CIPROFLOXACIN ingredient
Market Authorisation Date: 10 December, 2015
Treatment: NA
Dosage: INJECTABLE, SUSPENSION
More Information on Dosage
OTIPRIO family patents
66. Oxlumo patent expiration
Can you believe OXLUMO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11261447 | ALNYLAM PHARMS INC | Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
Nov, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-901) | Oct 06, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2025 |
| Orphan Drug Exclusivity(ODE-339) | Nov 23, 2027 |
| Orphan Drug Exclusivity(ODE-415) | Oct 06, 2029 |
Drugs and Companies using LUMASIRAN SODIUM ingredient
NCE-1 date: 23 November, 2024
Market Authorisation Date: 23 November, 2020
Treatment: Treatment of primary hyperoxaluria type 1 (ph1)
Dosage: SOLUTION
More Information on Dosage
OXLUMO family patents
67. Pedmark patent expiration
PEDMARK IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10596190 | FENNEC PHARMS INC | Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy |
Jan, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 20, 2025 |
| Orphan Drug Exclusivity(ODE-384) | Sep 20, 2029 |
Drugs and Companies using SODIUM THIOSULFATE ingredient
Market Authorisation Date: 20 September, 2022
Treatment: A method of reducing ototoxicity in a human pediatric patient about 5 years of age or under with localized medulloblastoma comprising administering sodium thiosulfate about six hours after administrat...
Dosage: SOLUTION
How can I launch a generic of PEDMARK before it's drug patent expiration?
More Information on Dosage
PEDMARK family patents
68. Posluma patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11413360 | BLUE EARTH | Dual mode radiotracer and—therapeutics |
Nov, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 25, 2028 |
Drugs and Companies using FLOTUFOLASTAT F-18 GALLIUM ingredient
NCE-1 date: 26 May, 2027
Market Authorisation Date: 25 May, 2023
Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer with suspected recurrence based on elevated serum prostate-specific antigen...
Dosage: SOLUTION
More Information on Dosage
POSLUMA family patents
69. Prevduo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10456354 | AZURITY | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(13 years from now) | |
| US11938217 | AZURITY | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(13 years from now) | |
| US11110054 | AZURITY | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(13 years from now) | |
Drugs and Companies using GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE ingredient
Market Authorisation Date: 23 February, 2023
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
PREVDUO family patents
70. Proair Digihaler patent expiration
PROAIR DIGIHALER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11351317 | TEVA BRANDED PHARM | Drug delivery device with electronics |
Feb, 2038
(13 years from now) | |
| US11357935 | TEVA BRANDED PHARM | Drug delivery device with electronics |
Sep, 2038
(13 years from now) | |
| US11000653 | TEVA BRANDED PHARM | Inhaler |
Dec, 2038
(14 years from now) | |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER, METERED
More Information on Dosage
PROAIR DIGIHALER family patents
71. Pyridostigmine Bromide patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12042559 | AMNEAL | Gastroretentive dosage forms for sustained drug delivery |
Jun, 2038
(13 years from now) | |
| US10925833 | AMNEAL | Extended release compositions comprising pyridostigmine |
Jun, 2038
(13 years from now) | |
| US10987311 | AMNEAL | Extended release compositions comprising pyridostigmine |
Jun, 2038
(13 years from now) | |
| US10881617 | AMNEAL | Extended release compositions comprising pyridostigmine |
Jun, 2038
(13 years from now) | |
| US11478425 | AMNEAL | Extended release compositions comprising pyridostigmine |
Jun, 2038
(13 years from now) | |
| US11666536 | AMNEAL | Extended release compositions comprising pyridostigmine |
Jun, 2038
(13 years from now) | |
| US11911515 | AMNEAL | Extended release compositions comprising pyridostigmine |
Jun, 2038
(13 years from now) | |
| US11229606 | AMNEAL | Extended release compositions comprising pyridostigmine |
Jun, 2038
(13 years from now) | |
Drugs and Companies using PYRIDOSTIGMINE BROMIDE ingredient
Market Authorisation Date: 04 October, 2024
Treatment: Pretreatment against the lethal effects of soman nerve agent poisoning
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
PYRIDOSTIGMINE BROMIDE family patents
72. Pyrukynd patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11254652 | AGIOS PHARMS INC | Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
Nov, 2038
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11234976 | AGIOS PHARMS INC | Methods of using pyruvate kinase activators |
Oct, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 17, 2027 |
| Orphan Drug Exclusivity(ODE-392) | Feb 17, 2029 |
Drugs and Companies using MITAPIVAT SULFATE ingredient
NCE-1 date: 17 February, 2026
Market Authorisation Date: 17 February, 2022
Treatment: Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency by administering a daily dose of 10mg to 100mg
Dosage: TABLET
More Information on Dosage
PYRUKYND family patents
73. Qvar Redihaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11865247 | NORTON WATERFORD | Inhalers and related methods |
Jan, 2038
(13 years from now) | |
| US11395888 | NORTON WATERFORD | Inhalers and related methods |
Jan, 2038
(13 years from now) | |
| US11793953 | NORTON WATERFORD | Inhalers and related methods |
Jan, 2038
(13 years from now) | |
| US11896759 | NORTON WATERFORD | Inhalers and related methods |
Jan, 2038
(13 years from now) | |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 03 August, 2017
Treatment: NA
Dosage: AEROSOL, METERED
More Information on Dosage
QVAR REDIHALER family patents
74. Retevmo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10584124 | LOXO ONCOL ELI LILLY | Crystalline forms |
Oct, 2038
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10786489 | LOXO ONCOL ELI LILLY | Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile |
Oct, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 08, 2025 |
| Orphan Drug Exclusivity(ODE-301) | May 08, 2027 |
| Orphan Drug Exclusivity(ODE-302) | May 08, 2027 |
| Orphan Drug Exclusivity(ODE-303) | May 08, 2027 |
| New Patient Population(NPP) | May 29, 2027 |
| Orphan Drug Exclusivity(ODE-409) | Sep 21, 2029 |
| Orphan Drug Exclusivity(ODE-412) | Sep 21, 2029 |
| Orphan Drug Exclusivity(ODE-484) | May 29, 2031 |
| Orphan Drug Exclusivity(ODE-485) | May 29, 2031 |
| Orphan Drug Exclusivity(ODE-487) | May 29, 2031 |
Drugs and Companies using SELPERCATINIB ingredient
NCE-1 date: 08 May, 2024
Market Authorisation Date: 08 May, 2020
Treatment: Treatment of adult or pediatric patients 2 years of age or older with advanced or metastatic thyroid cancer with a ret gene fusion, as detected by an fda-approved test, who require systemic therapy an...
Dosage: TABLET; CAPSULE
More Information on Dosage
RETEVMO family patents
75. Rezzayo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11819533 | MUNDIPHARMA | Compositions and methods for the treatment of fungal infections |
Jul, 2038
(13 years from now) | |
| US11197909 | MUNDIPHARMA | Compositions and methods for the treatment of fungal infections |
Jul, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2028 |
| Orphan Drug Exclusivity(ODE-426) | Mar 22, 2030 |
| Generating Antibiotic Incentives Now(GAIN) | Mar 22, 2033 |
Drugs and Companies using REZAFUNGIN ACETATE ingredient
NCE-1 date: 22 March, 2032
Market Authorisation Date: 22 March, 2023
Treatment: Treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration
Dosage: POWDER
More Information on Dosage
REZZAYO family patents
76. Rinvoq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11564922 | ABBVIE | Methods of treating crohn's disease and ulcerative colitis |
Mar, 2038
(13 years from now) | |
| US11607411 | ABBVIE | Methods of treating Crohn's disease and ulcerative colitis |
Mar, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
| New Indication(I-880) | Dec 14, 2024 |
| New Indication(I-883) | Jan 14, 2025 |
| New Indication(I-886) | Mar 16, 2025 |
| New Indication(I-888) | Apr 29, 2025 |
| New Indication(I-919) | May 18, 2026 |
| New Indication(I-946) | Apr 26, 2027 |
| New Patient Population(NPP) | Apr 26, 2027 |
| Orphan Drug Exclusivity(ODE-481) | Apr 26, 2031 |
Drugs and Companies using UPADACITINIB ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adults with moderately to severely active crohn's disease who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with moderately to severely a...
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
RINVOQ family patents
77. Rivfloza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11286488 | NOVO | Methods and compositions for inhibiting expression of LDHA |
Oct, 2038
(13 years from now) | |
| US11661604 | NOVO | Methods and compositions for inhibiting expression of LDHA |
Oct, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2028 |
| Orphan Drug Exclusivity(ODE-443) | Sep 29, 2030 |
Drugs and Companies using NEDOSIRAN SODIUM ingredient
NCE-1 date: 30 September, 2027
Market Authorisation Date: 29 September, 2023
Treatment: Method of treating primary hyperoxaluria type 1 (ph1)
Dosage: SOLUTION
More Information on Dosage
RIVFLOZA family patents
78. Rozlytrek patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11253515 | GENENTECH INC | Pharmaceutical compositions and dosage forms |
Jul, 2038
(13 years from now) | |
| US10398693 | GENENTECH INC | Pharmaceutical compositions and dosage forms |
Jul, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 15, 2024 |
| Orphan Drug Exclusivity(ODE-265) | Aug 15, 2026 |
| Orphan Drug Exclusivity(ODE-313) | Aug 15, 2026 |
| New Product(NP) | Oct 20, 2026 |
| New Patient Population(NPP) | Oct 20, 2026 |
| Orphan Drug Exclusivity(ODE-448) | Oct 20, 2030 |
Drugs and Companies using ENTRECTINIB ingredient
NCE-1 date: 16 August, 2023
Market Authorisation Date: 15 August, 2019
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
ROZLYTREK family patents
79. Ryaltris patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11679210 | GLENMARK SPECLT | Dispensing device and pharmaceutical composition for the treatment of rhinitis |
Sep, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 13, 2025 |
Drugs and Companies using MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 January, 2022
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
RYALTRIS family patents
80. Sincalide patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11318100 | MAIA PHARMS INC | Storage stable sincalide formulations |
Apr, 2038
(13 years from now) | |
| US11737983 | MAIA PHARMS INC | Storage stable sincalide formulations |
Apr, 2038
(13 years from now) | |
| US11110063 | MAIA PHARMS INC | Storage stable sincalide formulations |
Apr, 2038
(13 years from now) | |
Drugs and Companies using SINCALIDE ingredient
Market Authorisation Date: 22 November, 2022
Treatment: Stimulate gallbladder contraction. as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis; Diagnosis of gall bladde...
Dosage: POWDER
More Information on Dosage
SINCALIDE family patents
81. Sotalol Hydrochloride patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10512620 | ALTATHERA PHARMS LLC | Method of initiating and escalating sotalol hydrochloride dosing |
Aug, 2038
(13 years from now) | |
| US11696902 | ALTATHERA PHARMS LLC | Method of initiating and escalating sotalol hydrochloride dosing |
Aug, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 02, 2016 |
Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient
Market Authorisation Date: 02 July, 2009
Treatment: Intravenous sotalol dosing regimen for achieving steady state exposure in a facility that can provide electrocardiographic monitoring; Dosing regimen for intravenous sotalol for administration in a fa...
Dosage: SOLUTION
More Information on Dosage
SOTALOL HYDROCHLORIDE family patents
82. Sublocade patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10646484 | INDIVIOR | Methods to treat opioid use disorder |
Jun, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 30, 2020 |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 30 November, 2017
Treatment: Treatment of moderate to severe opioid use disorder
Dosage: SOLUTION, EXTENDED RELEASE
More Information on Dosage
SUBLOCADE family patents
83. Sunlenca patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11267799 | GILEAD SCIENCES INC | Solid forms of an HIV capsid inhibitor |
Aug, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2027 |
Drugs and Companies using LENACAPAVIR SODIUM ingredient
NCE-1 date: 22 December, 2026
Market Authorisation Date: 22 December, 2022
Treatment: NA
Dosage: SOLUTION; TABLET
More Information on Dosage
SUNLENCA family patents
84. Sunosi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10959976 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(13 years from now) | |
| US11865098 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(13 years from now) | |
| US11648232 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(13 years from now) | |
| US10912754 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-254) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa) with a dosing regimen that includes a dose of 75 mg once daily fo...
Dosage: TABLET
How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage
SUNOSI family patents
85. Symtuza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10786518 | JANSSEN PRODS | Compositions and methods of treating HIV |
Jul, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Combination(NC) | Jul 17, 2021 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 17 July, 2018
Treatment: Treatment of hiv-1 infection in adult or pediatric patients (>=40 kg) with <50 copies/ml hiv-1 rna after >= 6 months on prior antiretroviral regimen and no known darunavir or tenofovir resistance-asso...
Dosage: TABLET
How can I launch a generic of SYMTUZA before it's drug patent expiration?
More Information on Dosage
SYMTUZA family patents
86. Tadliq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11975006 | CMP DEV LLC | Liquid oral formulations for tadalafil |
Dec, 2038
(14 years from now) | |
| US11382917 | CMP DEV LLC | Liquid oral formulations for tadalafil |
Dec, 2038
(14 years from now) | |
| US11666576 | CMP DEV LLC | Liquid oral formulations for tadalafil |
Dec, 2038
(14 years from now) | |
Drugs and Companies using TADALAFIL ingredient
Market Authorisation Date: 17 June, 2022
Treatment: Tadliq is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability
Dosage: SUSPENSION
More Information on Dosage
TADLIQ family patents
87. Tafinlar patent expiration
Can you believe TAFINLAR received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11504333 | NOVARTIS | Pharmaceutical composition |
Jun, 2038
(13 years from now) | |
|
US11504333 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Dec, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-678) | Jan 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
| M(M-170) | Nov 20, 2018 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| Orphan Drug Exclusivity(ODE-47) | May 29, 2020 |
| New Indication(I-745) | Jun 22, 2020 |
| Orphan Drug Exclusivity(ODE-58) | Jan 09, 2021 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| M(M-246) | Oct 06, 2022 |
| Orphan Drug Exclusivity(ODE-147) | Jun 22, 2024 |
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| New Indication(I-894) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Sep 16, 2026 |
| New Indication(I-908) | Mar 16, 2026 |
| New Product(NP) | Mar 16, 2026 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
Drugs and Companies using DABRAFENIB MESYLATE ingredient
Market Authorisation Date: 16 March, 2023
Treatment: NA
Dosage: TABLET, FOR SUSPENSION
More Information on Dosage
TAFINLAR family patents
88. Thiola Ec patent expiration
THIOLA EC IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458104 | MISSION PHARMACAL | Enteric coated tiopronin tablet |
Nov, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | Jun 28, 2026 |
Drugs and Companies using TIOPRONIN ingredient
Market Authorisation Date: 28 June, 2019
Treatment: A method of treating cystinuria by orally administering tiopronin with food to prevent cystine stone formation in adults and pediatric patients with severe homozygous cystinuria
Dosage: TABLET, DELAYED RELEASE
How can I launch a generic of THIOLA EC before it's drug patent expiration?
More Information on Dosage
THIOLA EC family patents
89. Tryvio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10919881 | IDORSIA | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan |
Feb, 2038
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11787782 | IDORSIA | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
Mar, 2038
(13 years from now) | |
| US11680058 | IDORSIA | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan |
Jul, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2029 |
Drugs and Companies using APROCITENTAN ingredient
NCE-1 date: 22 March, 2028
Market Authorisation Date: 19 March, 2024
Treatment: Treatment of hypertension in combination with other antihypertensive drugs, including an angiotensin converting enzyme inhibitor, to lower blood pressure in adult patients who are not adequately contr...
Dosage: TABLET
More Information on Dosage
TRYVIO family patents
90. Tukysa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11666572 | SEAGEN | Treatment of HER2 positive cancers |
Apr, 2038
(13 years from now) | |
| US11207324 | SEAGEN | Treatment of HER2 positive cancers |
Apr, 2038
(13 years from now) | |
| US12048698 | SEAGEN | Treatment of HER2 positive cancers |
Apr, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
| New Indication(I-906) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-309) | Apr 17, 2027 |
| Orphan Drug Exclusivity(ODE-422) | Jan 19, 2030 |
Drugs and Companies using TUCATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: Combination treatment with tucatinib and trastuzumab of adults with ras wild-type her2-positive unresectable or metastatic colorectal cancer that has progressed following previous treatment as claimed
Dosage: TABLET
More Information on Dosage
TUKYSA family patents
91. Turalio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10941142 | DAIICHI SANKYO INC | Formulations of a compound modulating kinases |
Jul, 2038
(13 years from now) | |
| US10435404 | DAIICHI SANKYO INC | Formulations of a compound modulating kinases |
Jul, 2038
(13 years from now) | |
| US10961240 | DAIICHI SANKYO INC | Formulations of a compound modulating kinases |
Jul, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 02, 2024 |
| ODE*(ODE*) | Aug 02, 2026 |
| Orphan Drug Exclusivity(ODE-250) | Aug 02, 2026 |
Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient
NCE-1 date: 03 August, 2023
Market Authorisation Date: 14 October, 2022
Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery
Dosage: CAPSULE
More Information on Dosage
TURALIO family patents
92. Twyneo patent expiration
Can you believe TWYNEO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10420743 | GALDERMA LABS LP | Methods and compositions for the treatment of acne |
Jul, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 26, 2024 |
Drugs and Companies using BENZOYL PEROXIDE; TRETINOIN ingredient
Market Authorisation Date: 26 July, 2021
Treatment: Topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older
Dosage: CREAM
More Information on Dosage
TWYNEO family patents
93. Tymlos patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11782041 | RADIUS | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
Apr, 2038
(13 years from now) | |
| US11977067 | RADIUS | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
Apr, 2038
(13 years from now) | |
| US10996208 | RADIUS | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
Apr, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
| M(M-270) | Sep 20, 2024 |
| New Indication(I-907) | Dec 19, 2025 |
Drugs and Companies using ABALOPARATIDE ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Treatment to increase bone density in men with osteoporosis at high risk for fracture
Dosage: SOLUTION
How can I launch a generic of TYMLOS before it's drug patent expiration?
More Information on Dosage
TYMLOS family patents
94. Veklury patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10675296 | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(13 years from now) | |
| US11266681 | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(13 years from now) | |
| US11975017 | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-183) | Jan 21, 2025 |
| New Patient Population(NPP) | Apr 25, 2025 |
| New Chemical Entity Exclusivity(NCE) | Oct 22, 2025 |
| M(M-301) | Jul 13, 2026 |
| Pediatric Exclusivity(PED) | Jan 13, 2027 |
Drugs and Companies using REMDESIVIR ingredient
NCE-1 date: 13 January, 2026
Market Authorisation Date: 22 October, 2020
Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (birth to < 18 years of age weighing > 1.5 kg) requiring hospitalization
Dosage: POWDER; SOLUTION
More Information on Dosage
VEKLURY family patents
95. Vevye patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11154513 | HARROW EYE | Semifluorinated compounds |
Nov, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 30, 2026 |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 30 May, 2023
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION
More Information on Dosage
VEVYE family patents
96. Voydeya patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12076319 | ALEXION PHARMS INC | Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria |
Aug, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2029 |
| Orphan Drug Exclusivity(ODE-476) | Mar 29, 2031 |
Drugs and Companies using DANICOPAN ingredient
NCE-1 date: 29 March, 2028
Market Authorisation Date: 29 March, 2024
Treatment: Treatment of extravascular hemolysis (evh) in adults with paroxysmal nocturnal hemoglobinuria (pnh) as add-on therapy to ravulizumab or eculizumab
Dosage: TABLET
More Information on Dosage
VOYDEYA family patents
97. Vtama patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11597692 | DERMAVANT SCI | Process for preparing tapinarof |
Nov, 2038
(13 years from now) | |
| US10647649 | DERMAVANT SCI | Process for preparing tapinarof |
Nov, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 23, 2027 |
Drugs and Companies using TAPINAROF ingredient
NCE-1 date: 23 May, 2026
Market Authorisation Date: 23 May, 2022
Treatment: NA
Dosage: CREAM
More Information on Dosage
VTAMA family patents
98. Wegovy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11752198 | NOVO | GLP-1 compositions and uses thereof |
Aug, 2038
(13 years from now) | |
| US10888605 | NOVO | GLP-1 compositions and uses thereof |
Aug, 2038
(13 years from now) | |
| US12029779 | NOVO | Semaglutide in medical therapy |
Oct, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Product(NP) | Jun 04, 2024 |
| New Patient Population(NPP) | Dec 23, 2025 |
| New Dosing Schedule(D-190) | Jul 21, 2026 |
| New Indication(I-935) | Mar 08, 2027 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 04 June, 2021
Treatment: Method for weight management
Dosage: SOLUTION
How can I launch a generic of WEGOVY before it's drug patent expiration?
More Information on Dosage
WEGOVY family patents
99. Xdemvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10835517 | TARSUS | Methods for treating ocular demodex using isoxazoline parasiticide formulations |
Dec, 2038
(13 years from now) | |
| US11197847 | TARSUS | Isoxazoline parasiticide formulations and methods for treating blepharitis |
Dec, 2038
(13 years from now) | |
| US11690827 | TARSUS | Methods for treating ocular Demodex using lotilaner formulations |
Dec, 2038
(13 years from now) | |
| US11752137 | TARSUS | Ophthalmic compositions for treating ocular Demodex using lotilaner formulations |
Dec, 2038
(13 years from now) | |
| US11690826 | TARSUS | Methods for treating demodex blepharitis using lotilaner formulations |
Dec, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2028 |
Drugs and Companies using LOTILANER ingredient
NCE-1 date: 25 July, 2027
Market Authorisation Date: 24 July, 2023
Treatment: Treatment of demodex blepharitis via topical administration to an ocular surface
Dosage: SOLUTION/DROPS
More Information on Dosage
XDEMVY family patents
100. Xofluza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11261198 | GENENTECH INC | Process for preparing substituted polycyclic pyridone derivative and crystal thereof |
Sep, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-811) | Oct 16, 2022 |
| New Chemical Entity Exclusivity(NCE) | Oct 24, 2023 |
Drugs and Companies using BALOXAVIR MARBOXIL ingredient
NCE-1 date: 24 October, 2022
Market Authorisation Date: 24 October, 2018
Treatment: NA
Dosage: TABLET; FOR SUSPENSION
How can I launch a generic of XOFLUZA before it's drug patent expiration?
More Information on Dosage
XOFLUZA family patents
101. Xolremdi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12115156 | X4 PHARMS | Compositions of CXCR4 inhibitors and methods of preparation and use |
Dec, 2038
(13 years from now) | |
| US11045461 | X4 PHARMS | Compositions of CXCR4 inhibitors and methods of preparation and use |
Dec, 2038
(13 years from now) | |
| US10548889 | X4 PHARMS | Compositions of CXCR4 inhibitors and methods of preparation and use |
Dec, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 26, 2029 |
| Orphan Drug Exclusivity(ODE-480) | Apr 26, 2031 |
Drugs and Companies using MAVORIXAFOR ingredient
NCE-1 date: 26 April, 2028
Market Authorisation Date: 26 April, 2024
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
XOLREMDI family patents
102. Xyosted (autoinjector) patent expiration
Can you believe XYOSTED (AUTOINJECTOR) received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10646495 | ANTARES PHARMA INC | Testosterone ester triglyceride formulations |
Aug, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 28, 2021 |
Drugs and Companies using TESTOSTERONE ENANTHATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
XYOSTED (AUTOINJECTOR) family patents
103. Ycanth patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11147790 | VERRICA PHARMS | Treatment of cutaneous disorders |
Aug, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 21, 2028 |
Drugs and Companies using CANTHARIDIN ingredient
NCE-1 date: 22 July, 2027
Market Authorisation Date: 21 July, 2023
Treatment: Topical treatment of skin lesions caused by an infection with molluscum contagiosum in adult and pediatric patients 2 years of age and older
Dosage: SOLUTION
More Information on Dosage
YCANTH family patents
104. Zejula patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11673877 | GLAXOSMITHKLINE | Niraparib compositions |
Mar, 2038
(13 years from now) | |
| US11091459 | GLAXOSMITHKLINE | Niraparib compositions |
Mar, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2022 |
| New Indication(I-813) | Oct 23, 2022 |
| New Indication(I-814) | Oct 23, 2022 |
| New Indication(I-833) | Apr 29, 2023 |
| Orphan Drug Exclusivity(ODE) | Mar 27, 2024 |
| Orphan Drug Exclusivity(ODE-133) | Mar 27, 2024 |
| Orphan Drug Exclusivity(ODE-277) | Oct 23, 2026 |
| Orphan Drug Exclusivity(ODE-278) | Oct 23, 2026 |
| Orphan Drug Exclusivity(ODE-295) | Apr 29, 2027 |
Drugs and Companies using NIRAPARIB TOSYLATE ingredient
NCE-1 date: 27 March, 2021
Market Authorisation Date: 27 March, 2017
Treatment: A method of treatment of ovarian cancer or fallopian tube cancer
Dosage: TABLET
More Information on Dosage
ZEJULA family patents
105. Zeposia patent expiration
Can you believe ZEPOSIA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11680050 | BRISTOL | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof |
Sep, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-860) | May 27, 2024 |
| New Chemical Entity Exclusivity(NCE) | Mar 25, 2025 |
| M(M-309) | Aug 30, 2027 |
Drugs and Companies using OZANIMOD HYDROCHLORIDE ingredient
NCE-1 date: 25 March, 2024
Market Authorisation Date: 25 March, 2020
Treatment: Treatment of moderately to severely active ulcerative colitis (uc) in adults
Dosage: CAPSULE
More Information on Dosage
ZEPOSIA family patents
106. Zonisade patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11478456 | AZURITY | Oral pharmaceutical composition comprising Zonisamide and process of preparation thereof |
Aug, 2038
(13 years from now) | |
| US11529333 | AZURITY | Oral pharmaceutical composition comprising zonisamide and process of preparation thereof |
Aug, 2038
(13 years from now) | |
Drugs and Companies using ZONISAMIDE ingredient
Market Authorisation Date: 15 July, 2022
Treatment: A method of treating seizures
Dosage: SUSPENSION
More Information on Dosage
ZONISADE family patents
List of large molecules
1. List of Eylea large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10918754 | REGENERON PHARMACEUTICALS, INC. | Sterilisation method |
Mar, 2038
(13 years from now) | |
| US10905786 | REGENERON PHARMACEUTICALS, INC. | Sterilisation method |
Mar, 2038
(13 years from now) | |
| US11788102 | REGENERON PHARMACEUTICALS, INC. | CHO integration sites and uses thereof |
Sep, 2038
(13 years from now) | |
| US11769597 | REGENERON PHARMACEUTICALS, INC. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
Dec, 2038
(13 years from now) | |
| US11433186 | REGENERON PHARMACEUTICALS, INC. | Devices and methods for precision dose delivery |
Dec, 2038
(13 years from now) |
Ingredients: AFLIBERCEPT